BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29656114)

  • 1. Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.
    Weston VJ; Wei W; Stankovic T; Kearns P
    Exp Hematol; 2018 Jul; 63():52-63.e5. PubMed ID: 29656114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upstream and downstream mechanisms for the promoting effects of IGF-1 on differentiation of spermatogonia to primary spermatocytes.
    Shen G; Wu R; Liu B; Dong W; Tu Z; Yang J; Xu Z; Pan T
    Life Sci; 2014 Apr; 101(1-2):49-55. PubMed ID: 24582811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
    Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
    Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
    Hu Y; Dragowska WH; Wallis A; Duronio V; Mayer L
    Breast Cancer Res Treat; 2001 Nov; 70(1):11-20. PubMed ID: 11767000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
    Champelovier P; El Atifi M; Pautre V; Rostaing B; Berger F; Seigneurin D
    Exp Hematol; 2008 Jan; 36(1):28-36. PubMed ID: 17949889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells.
    Furuhashi S; Sugita H; Takamori H; Horino K; Nakahara O; Okabe H; Miyake K; Tanaka H; Beppu T; Baba H
    Int J Oncol; 2012 Mar; 40(3):807-15. PubMed ID: 22025280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.
    Kawashima I; Mitsumori T; Nozaki Y; Yamamoto T; Shobu-Sueki Y; Nakajima K; Kirito K
    Exp Hematol; 2015 Jul; 43(7):524-33.e1. PubMed ID: 25846811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase.
    Kooijman R; Coppens A; Hooghe-Peters E
    Cell Signal; 2003 Dec; 15(12):1091-8. PubMed ID: 14575864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
    Jang K; Kim M; Seo HS; Shin I
    Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
    J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
    Yip-Schneider MT; Schmidt CM
    Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
    Fukazawa H; Noguchi K; Murakami Y; Uehara Y
    Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
    Bancroft CC; Chen Z; Dong G; Sunwoo JB; Yeh N; Park C; Van Waes C
    Clin Cancer Res; 2001 Feb; 7(2):435-42. PubMed ID: 11234901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
    Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
    Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor.
    Lecat S; Belemnaba L; Galzi JL; Bucher B
    Cell Signal; 2015 Jul; 27(7):1297-304. PubMed ID: 25817573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells.
    Gingras S; Côté S; Simard J
    Mol Endocrinol; 2000 Feb; 14(2):229-40. PubMed ID: 10674396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
    Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
    Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.